Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Pre-Mkt 06-12 07:46:52 EDT

6.50

-0.08

-1.22%

盘前6.57

+0.07+1.10%

06:30 EDT

High6.71	Low6.29	Vol973.04K
Open6.59	D1 Closing6.58	Amplitude6.46%
Mkt Cap203.38M	Tradable Cap102.00M	Total Shares31.29M
T/O6.29M	T/O Rate6.20%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":6.5,"timestamp":1781208000000,"preClose":6.58,"halted":0,"volume":973043,"hourTrading":{"tag":"盘前","latestPrice":6.5713,"preClose":6.5,"latestTime":"06:30 EDT","volume":1640,"amount":10665.43578,"timestamp":1781260235059,"change":0.0713,"changeRate":0.010969,"amplitude":0.018462},"delay":0,"changeRate":-0.012158054711246211,"floatShares":15692500,"shares":31289969,"eps":-3.661292,"marketStatus":"Pre-Mkt","change":-0.08,"latestTime":"06-12 07:46:52 EDT","open":6.59,"high":6.71,"low":6.285,"amount":6285159.5243432,"amplitude":0.06459,"askPrice":6.6,"askSize":101,"bidPrice":6.51,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781271000000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":6.5,"preHourTrading":{"tag":"盘前","latestPrice":6.5713,"preClose":6.5,"latestTime":"06:30 EDT","volume":1640,"amount":10665.43578,"timestamp":1781260235059,"change":0.0713,"changeRate":0.010969,"amplitude":0.018462},"postHourTrading":{"tag":"盘后","latestPrice":6.5,"preClose":6.5,"latestTime":"19:59 EDT","volume":9618,"amount":62474.366,"timestamp":1781222391229,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.5885342429238842,"impliedVol":1.4565,"impliedVolPercentile":0.964},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2642926798","title":"Press Release: Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2642926798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642926798?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:10","pubTimestamp":1781262600,"startTime":"0","endTime":"0","summary":"14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less. MEQUON, Wis., June 12, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp.  today announced the appointment of Dexter Fowler as Chief Athletic Officer for Valor, its sports medicine division built to bring Vector's transdermal peptide platform to elite athletes and the sports medicine professionals who care for them. Fowler, a 2016 World Series Champion and Olympic bronze medalist, will lead athlete engagement and onboarding across professional sports.Fowler spent fourteen seasons as a center fielder and leadoff hitter for the Colorado Rockies, Houston Astros, Chicago Cubs, St. Louis Cardinals, and Los Angeles Angels. He is best known for leading off Game 7 of the 2016 World Series with a home run that ignited the Cubs' first championship in 108 years. After retiring, he founded 400 Ventures, an athlete and entertainment managemen","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","VAQC","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642262912","title":"Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2642262912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642262912?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:28","pubTimestamp":1781260117,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($ATHE) ) has provided an announcement. Alterity Therapeutics, listed on the ASX and Nasdaq, develops disease-modifying the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-completes-50-for-1-capital-consolidation-after-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-completes-50-for-1-capital-consolidation-after-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","NQmain","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264760","title":"Enliven Therapeutics Prices $400 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264760","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642264760?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:21","pubTimestamp":1781259681,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  priced an upsized public offering of 8.9 million shares at $37.50 per share and pre-funded warrants to purchase up to 1.73 million shares at $37.499 each, the company said.The offering, expected to close Monday, is expected to raise gross proceeds of around $400 million, the company said.The company has also granted underwriters a 30-day option to purchase up to 1.6 million additional shares, it said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELVN","BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642491264","title":"EXACT Therapeutics Shareholders Approve All Resolutions at 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2642491264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642491264?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:04","pubTimestamp":1781258665,"startTime":"0","endTime":"0","summary":"An update from EXACT Therapeutics AS ( ($DE:56F) ) is now available. EXACT Therapeutics AS has announced that all resolutions proposed at its Annua...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-shareholders-approve-all-resolutions-at-2026-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-shareholders-approve-all-resolutions-at-2026-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","BK4007","BK4202","BK4139","BK4195","LENZ","AS","BK4539","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261736","title":"Avalo Therapeutics initiated with a Buy at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642261736?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:51","pubTimestamp":1781257877,"startTime":"0","endTime":"0","summary":"BofA initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $35 price target The firm sees Avalo as a “cleaner, single-asset immunol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238263","title":"Autolus Therapeutics Receives Prix Galien UK Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238263","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238263?lang=en_us&edition=fundamental","pubTime":"2026-06-12 16:00","pubTimestamp":1781251200,"startTime":"0","endTime":"0","summary":"LONDON and GAITHERSBURG, Md., June  12, 2026  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-ge","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/12/3310914/0/en/Autolus-Therapeutics-Receives-Prix-Galien-UK-Award.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642252256","title":"Allergy Therapeutics Highlights Positive Allergy Trial Data at EAACI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642252256","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642252256?lang=en_us&edition=fundamental","pubTime":"2026-06-12 14:09","pubTimestamp":1781244570,"startTime":"0","endTime":"0","summary":"Allergy Therapeutics ( ($GB:AGY) ) just unveiled an announcement. Allergy Therapeutics will showcase data from its pollen and food allergy research...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-highlights-positive-allergy-trial-data-at-eaaci-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-highlights-positive-allergy-trial-data-at-eaaci-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230058","title":"Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230058?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:05","pubTimestamp":1781222711,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) said it dosed over 50% of participants in the first regimen of a trial evaluating NUZ-001 for the treatment of amyotrophic lateral sclerosis, or ALS, according to a Fri","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","NUZ.AU","BK4007","BK4139","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642323772","title":"Quince Therapeutics Stockholders Approve Reverse Split Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2642323772","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642323772?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:42","pubTimestamp":1781217761,"startTime":"0","endTime":"0","summary":"Quince Therapeutics ( ($QNCX) ) has provided an update. On June 11, 2026, Quince Therapeutics held its annual meeting of stockholders via live webc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-stockholders-approve-reverse-split-authorization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-stockholders-approve-reverse-split-authorization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642232954","title":"Tvardi Therapeutics Shareholders Approve Directors and Governance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2642232954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642232954?lang=en_us&edition=fundamental","pubTime":"2026-06-12 05:05","pubTimestamp":1781211922,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics ( ($TVRD) ) just unveiled an announcement. On June 9, 2026, Tvardi Therapeutics, Inc. held its Annual Meeting of Stockholders, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-shareholders-approve-directors-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-shareholders-approve-directors-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642236083","title":"Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2642236083","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642236083?lang=en_us&edition=fundamental","pubTime":"2026-06-12 02:05","pubTimestamp":1781201124,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on SLN stock, giving a Buy rating on June 2. Myles Minter has given his Buy ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/silence-therapeutics-earns-buy-rating-on-promising-divesiran-phase-i-data-and-best-in-class-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/silence-therapeutics-earns-buy-rating-on-promising-divesiran-phase-i-data-and-best-in-class-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642723554","title":"Tango Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2642723554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642723554?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:18","pubTimestamp":1781194680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 12:18 ET (16:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642337952","title":"Adial Pharmaceuticals announces acquisition of Azora Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2642337952","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642337952?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:50","pubTimestamp":1781193009,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145047069","title":"Viking Therapeutics Appoints Dr. Hubert C. Chen as New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1145047069","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145047069?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:10","pubTimestamp":1781190640,"startTime":"0","endTime":"0","summary":"Clinical-stage biopharmaceutical company Viking Therapeutics announced on Thursday the appointment of Dr. Hubert C. Chen as its new Chief Medical Officer. Dr. Chen will be responsible for leading the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","159891","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642382872","title":"Kazia Therapeutics Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2642382872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642382872?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:02","pubTimestamp":1781190120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KZIA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 11:02 ET (15:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4007","KZIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193827468","title":"Silence Therapeutics Unveils Extended Divesiran Follow-Up Data Demonstrating Sustained Efficacy and Best-in-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1193827468","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193827468?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:30","pubTimestamp":1781188250,"startTime":"0","endTime":"0","summary":"Silence Therapeutics this week presented updated follow-up data from the Phase 1 SANRECO study of its investigational siRNA therapy, divesiran, at the 2026 European Hematology Association Annual...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642428036","title":"Summit Therapeutics Withdraws Public Offering Due to Market Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642428036?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:57","pubTimestamp":1781186244,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  has withdrawn its proposed underwritten public offering of securities, due to market conditions, the company said in a Thursday regulatory filing.The company had announced the launch of an underwritten public offering of $500 million of its common stock on Tuesday.Price: 13.49, Change: +0.43, Percent Change: +3.33","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","BK4139","BK4539","SMMF","BK4211","SMMT","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280500","title":"Summit Therapeutics withdraws proposed underwritten public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280500?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:50","pubTimestamp":1781185822,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Summit Therapeutics (SMMT) announced that effective June 10, 2026 it has withdrawn its previously announced proposed underw...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-withdraws-proposed-underwritten-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-withdraws-proposed-underwritten-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMF","BK4539","BK4139","BK4007","LU2488822045.USD","BK4211","SMMT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642827432","title":"Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642827432","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642827432?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:11","pubTimestamp":1781183479,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  said Thursday that it has reached alignment with the US Food and Drug Administration on the 80 mg once daily dose of ELVN-001 in a planned late-stage trial for chronic myeloid leukemia.The company said the trial will enroll patients with chronic myeloid leukemia who have previously been treated with one or more tyrosine kinase inhibitors, or TKIs, and will receive either ELVN-001 or the physician's choice of ATP-competitive TKI.Enliven said additional details on late-stage trial design will be finalized after another meeting with the FDA in Q3, with the study set to begin in the second half of this year.Enliven also published data from the first phase of the study. In the 80 mg QD phase 1b cohort, the overall major molecular response by 24 weeks was 61%, with 67% in patients who had previously received one or two unique TKIs, it said.Shares of the company were up 22% in recent Thursday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELVN","BK4539","BK4588","BK4139","BK4585","LENZ","BK4007","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282629","title":"Atossa Therapeutics Announces Registered Direct Offering and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282629","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282629?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:41","pubTimestamp":1781181664,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics ( ($ATOS) ) just unveiled an announcement. On June 10, 2026, Atossa Therapeutics, Inc. entered into a securities purchase agree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atossa-therapeutics-announces-registered-direct-offering-and-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atossa-therapeutics-announces-registered-direct-offering-and-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0972},{"period":"1month","weight":-0.1783},{"period":"3month","weight":-0.465},{"period":"6month","weight":-0.6417},{"period":"1year","weight":-0.7833},{"period":"ytd","weight":-0.5938}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":0.011151},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction